Golgi apparatus targeted therapy in cancer: Are we there yet?

• Published in: LIFE SCIENCES
• Main Authors: Lee, Zheng Yang; Lee, Wen Hwei; Lim, Jing Sheng; Ali, Afiqah Ali Ajmel; Loo, Jason Siau Ee; Wibowo, Agustono; Mohammat, Mohd Fazli; Foo, Jhi Biau
• Format: Article
• Language: English
• Published: PERGAMON-ELSEVIER SCIENCE LTD 2024
• Subjects: Research & Experimental Medicine; Pharmacology & Pharmacy
• Online Access: https://www-webofscience-com.uitm.idm.oclc.org/wos/woscc/full-record/WOS:001263515200001
• ISSN: 0024-3205; 1879-0631
• DOI: 10.1016/j.lfs.2024.122868

Membrane trafficking within the Golgi apparatus plays a pivotal role in the intracellular transportation of lipids and proteins. Dysregulation of this process can give rise to various pathological manifestations, including cancer. Exploiting Golgi defects, cancer cells capitalise on aberrant membrane trafficking to facilitate signal transduction, proliferation, invasion, immune modulation, angiogenesis, and metastasis. Despite the identification of several molecular signalling pathways associated with Golgi abnormalities, there remains a lack of approved drugs specifically targeting cancer cells through the manipulation of the Golgi apparatus. In the initial section of this comprehensive review, the focus is directed towards delineating the abnormal Golgi genes and proteins implicated in carcinogenesis. Subsequently, a thorough examination is conducted on the impact of these variations on Golgi function, encompassing aspects such as vesicular trafficking, glycosylation, autophagy, oxidative mechanisms, and pH alterations. Lastly, the review provides a current update on promising Golgi apparatustargeted inhibitors undergoing preclinical and/or clinical trials, offering insights into their potential as therapeutic interventions. Significantly more effort is required to advance these potential inhibitors to benefit patients in clinical settings.